middle.news
Imugene Secures $5.87M R&D Refund to Accelerate Cancer Therapy Trials
9:50am on Friday 4th of July, 2025 AEST
•
Healthcare
Read Story
Imugene Secures $5.87M R&D Refund to Accelerate Cancer Therapy Trials
9:50am on Friday 4th of July, 2025 AEST
Key Points
Received $5.87 million R&D tax refund for FY2024
Funds to accelerate clinical development of immuno-oncology pipeline
Pipeline includes CAR T cell therapy, B-cell vaccines, and oncolytic virotherapy
Refund includes $84,990 interest under Australian Government incentive
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE